Die Marktgre fr Tirzepatid im Markt fr GLP-1-Agonisten knnte bis 2031 38 Milliarden USD erreichen, wenn die aktuellen Studiendaten positiv bleiben und die Kapazittserweiterungen planmig verlaufen
Pioneer 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes
For patients with obesity and high cardiovascular risk, GLP-1 receptor agonists often represent the first choice
1 Amla berry also protects against radiation damage
Quick Stats for GLP-1 Obesity Home Delivery Injectables Market GLP-1 Obesity Home Delivery Injectables Market Value (2026): USD 2.9 Billion GLP-1 Obesity Home Delivery Injectables Market Forecast Value (2036): USD 11.1 Billion GLP-1 Obesity Home Delivery Injectables Market Forecast CAGR 2026 to 2036: 14.90% Leading Molecule in GLP-1 Obesity Home Delivery Injectables Market: Semaglutide Leading Patient Type in GLP-1 Obesity Home Delivery Injectables Market: Chronic Obesity Key Growth Regions in GLP-1 Obesity Home Delivery Injectables Market: North America, Europe, Asia Pacific Top Key Players in GLP-1 Obesity Home Delivery Injectables Market: Novo Nordisk, Eli Lilly, AstraZeneca, Pfizer, Amgen, Roche Metric How Is the Global GLP-1 Obesity Home Delivery Injectables Market Advancing
Received: 11 Jun 2025 | Revised: 29 Jul 2025 | Accepted: 31 Jul 2025 | Published: 27 Jan 2026 1